Comparison of two Mycoplasma genitalium real-time PCR detection methodologies.

Department of Microbiology & Infectious Diseases, The Royal Women's Hospital, Melbourne, Australia.
Journal of clinical microbiology (Impact Factor: 4.16). 01/2011; 49(3):1140-2. DOI: 10.1128/JCM.02328-10
Source: PubMed

ABSTRACT Established in-house quantitative PCR (qPCR) assays to detect the Mycoplasma genitalium adhesion protein (MgPa) and the 16S rRNA gene were found to be comparable for screening purposes, with a kappa value of 0.97 (95% confidence interval [CI], 0.94 to 1.01) and no difference in bacterial load quantified (P = 0.4399).

  • [Show abstract] [Hide abstract]
    ABSTRACT: Mycoplasma genitalium is a globally important sexually transmitted pathogen. Men infected with M. genitalium frequently present with dysuria, while women may present with or without urogenital symptoms. In some populations, M. genitalium is significantly associated with HIV-1 infection, and is also an etiological agent in pelvic inflammatory disease. However, there is insufficient evidence to establish a causative role of the organism in obstetric complications, including tubal factor infertility. Although several nucleic acid amplification tests offer rapid, sensitive methods for detecting M. genitalium, there is no standardized assay. Available evidence supports treatment of M. genitalium infections with an extended regimen of azithromycin and resistant strains respond to moxifloxacin. Accumulating evidence indicates growing fluoroquinolone resistance, including against moxifloxacin, emphasizing the need for new therapeutic strategies to treat M. genitalium infections.
    Expert Review of Anticancer Therapy 04/2012; 10(4):487-99. · 3.22 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Differences in the determinants of Chlamydia trachomatis ('chlamydia') and Mycoplasma genitalium (MG) genital infection in women are not well understood. A cohort study of 16 to 25 year old Australian women recruited from primary health care clinics, aimed to determine chlamydia and MG prevalence and incidence. Vaginal swabs collected at recruitment were used to measure chlamydia and MG prevalence, organism-load and chlamydia-serovar a cross-sectional analysis undertaken on the baseline results is presented here. Of 1116 participants, chlamydia prevalence was 4.9% (95% CI: 2.9, 7.0) (n = 55) and MG prevalence was 2.4% (95% CI: 1.5, 3.3) (n = 27). Differences in the determinants were found - chlamydia not MG, was associated with younger age [AOR:0.9 (95% CI: 0.8, 1.0)] and recent antibiotic use [AOR:0.4 (95% CI: 0.2, 1.0)], and MG not chlamydia was associated with symptoms [AOR:2.1 (95% CI: 1.1, 4.0)]. Having two or more partners in last 12 months was more strongly associated with chlamydia [AOR:6.4 (95% CI: 3.6, 11.3)] than MG [AOR:2.2 (95% CI: 1.0, 4.6)] but unprotected sex with three or more partners was less strongly associated with chlamydia [AOR:3.1 (95%CI: 1.0, 9.5)] than MG [AOR:16.6 (95%CI: 2.0, 138.0)]. Median organism load for MG was 100 times lower (5.7 × 104/swab) than chlamydia (5.6 × 106/swab) (p < 0.01) and not associated with age or symptoms for chlamydia or MG. These results demonstrate significant chlamydia and MG prevalence in Australian women, and suggest that the differences in strengths of association between numbers of sexual partners and unprotected sex and chlamydia and MG might be due to differences in the transmission dynamics between these infections.
    BMC Infectious Diseases 01/2011; 11:35. · 3.03 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background. Mycoplasma genitalium (MG) is an emerging sexually transmitted infection (STI) that is potentially associated with serious reproductive tract sequelae in women. This study aimed to estimate rates of MG incidence and treatment failure and provide estimates of organism load for MG infections.Methods. 1110 women aged 16 to 25 years were recruited from primary care clinics in Australia. Women were tested for MG at baseline, 6 months and 12 months and MG organism load was measured by quantitative PCR. All MG positive cases were also screened for MG 23S rRNA gene point mutations shown to confer azithromycin resistance using high resolution melt following PCR.Results. MG incidence rate was 1.3 per 100 person years (95% CI: 0.8, 2.3) (n=14) and women reporting three or more sex partners in the last 12 months had an increased rate of incident infection [RR=5.1 (95%CI: 1.3, 19.6)]. There were 3 cases of MG re-infection with a re-infection rate of 0.8 per 100 person years (95% CI: 0.1, 0.9). Organism load was higher for prevalent than incident infection (p=0.04). There were 3 cases of treatment failure cases [9.4% (95%CI: 2.0, 25.0)] and organism load was higher in the cases with treatment failure than the successfully treated cases (p<0.01). An MG 23S rRNA mutation was detected in 5 cases; 3 cases of treatment failure and 2 successfully treated cases.Conclusions. While MG incidence was relatively low, testing should be recommended for women considered to be at increased risk of infection based on sexual history. Our results also suggest that organism load might be important in influencing azithromycin treatment failure.
    Clinical Infectious Diseases 01/2013; · 9.37 Impact Factor

Full-text (2 Sources)

Available from
May 23, 2014